Eyes of the world on case concerning best-ever-selling drug
No company makes more money from a drug than US pharma major AbbVie (NYSE: ABBV) does from its arthritis treatment Humira (adalimumab), but how long that will go on for could be determined by a UK court case starting on Monday.
The trial pits AbbVie, which attempted to stop the proceedings taking place, as the defendant and the holder of a number of patents relating to Humira, against the claimants, Japan’s Fujifilm Kyowa Kirin Biologics (FKB) and South Korean drug developer Samsung Bioepis, a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB).
The latter two companies are seeking to clear the way of secondary patents so that, upon expiry of Humira’s basic patent in October 2018, they will be able to launch biosimilar versions of the drug, which has been approved to treat rheumatoid arthritis, psoriatic arthritis and psoriasis, and achieved net sales in 2015 in excess of $14 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze